Lung Function in ILD Patients Request More Information Trial Objective The purpose of this study is to look at the effect of trans sodium crocetinate (TSC) on lung function. It is thought that TSC will improve the body's ability to deliver oxygen to oxygen-deprived tissue. Researchers hope that TSC will improve lung function in people with ILD. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People who have been diagnosed with ILD may be eligible to participate in this study. Age: 30-85 Gender: Any Gender Estimated Time Commitment Up to 31 days he screening period is up to 28 days. The treatment period is one day. A follow up 1 hour phone call visit 48 hours after the treatment period. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Hannah Slowey 303.398.1233 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Diffusion Pharmaceuticals, Inc. Principal Investigators Michael Mohning, MD + × Michael Mohning, MD Assistant Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine Interstitial Lung Disease Program View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective The purpose of this study is to look at the effect of trans sodium crocetinate (TSC) on lung function. It is thought that TSC will improve the body's ability to deliver oxygen to oxygen-deprived tissue. Researchers hope that TSC will improve lung function in people with ILD.